Verona Pharma PLC ADR - Asset Resilience Ratio
Verona Pharma PLC ADR (VRNA) has an Asset Resilience Ratio of 0.00% as of September 2020. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. Check strategic asset allocation of Verona Pharma PLC ADR to assess the company's strategic physical and investment asset allocation.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio Trend (2006–2020)
This chart shows how Verona Pharma PLC ADR's Asset Resilience Ratio has changed over time. See debt-free asset ratio of Verona Pharma PLC ADR to measure how much of total assets are equity-financed.
Liquid Assets Composition Over Time
This chart breaks down Verona Pharma PLC ADR's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For market capitalisation and broader financial context, see VRNA company net worth.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 0% |
| Short-term Investments | $0.00 | 0% |
| Total Liquid Assets | $0.00 | 0.00% |
Asset Resilience Insights
- Limited Liquidity: Verona Pharma PLC ADR maintains only 0.00% of assets in liquid form.
- This low level may indicate efficient asset utilization but could pose risks during economic downturns.
- The company maintains a balanced mix of cash and short-term investments.
Verona Pharma PLC ADR Industry Peers by Asset Resilience Ratio
Compare Verona Pharma PLC ADR's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
Argen-X
F:1AE |
Biotechnology | 10.93% |
|
CSL Ltd
AU:CSL |
Biotechnology | 0.41% |
|
Tango Therapeutics Inc
NASDAQ:TNGX |
Biotechnology | 57.90% |
|
HLB Co. Ltd
KQ:028300 |
Biotechnology | 0.72% |
|
SOLENO THERAPEUT. DL-001
F:6XC |
Biotechnology | 41.74% |
|
MBX Biosciences, Inc. Common Stock
NASDAQ:MBX |
Biotechnology | 87.20% |
|
Tourmaline Bio Inc.
NASDAQ:TRML |
Biotechnology | 77.17% |
|
PharmaResources (Shanghai) Co. Ltd. A
SHE:301230 |
Biotechnology | 16.35% |
Annual Asset Resilience Ratio for Verona Pharma PLC ADR (2006–2020)
The table below shows the annual Asset Resilience Ratio data for Verona Pharma PLC ADR.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2020-12-31 | 5.02% | $10.26 Million | $204.21 Million | -12.31pp |
| 2019-12-31 | 17.33% | $10.26 Million | $59.18 Million | -43.16pp |
| 2018-12-31 | 60.49% | $57.00 Million | $94.23 Million | +5.94pp |
| 2017-12-31 | 54.54% | $65.97 Million | $120.96 Million | -- |
| 2016-12-31 | 0.00% | $0.00 | $56.93 Million | -- |
| 2015-12-31 | 0.00% | $0.00 | $10.96 Million | -- |
| 2014-12-31 | 0.00% | $0.00 | $20.43 Million | -- |
| 2006-12-31 | 32.80% | $2.55 Million | $7.77 Million | -- |
About Verona Pharma PLC ADR
Verona Pharma plc, a biopharmaceutical company, focuses on development and commercialization of therapies for the treatment of respiratory diseases with unmet medical needs. The company offers Ohtuvayre, a dual inhibitor of the phosphodiesterase (PDE) 3 and PDE4 enzymes that combines bronchodilator and non-steroidal anti-inflammatory effects for the maintenance treatment of chronic obstructive pu… Read more